Добірка наукової літератури з теми "Empty virus like particles"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Empty virus like particles".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Empty virus like particles"

1

Wu, Hui-Lin, Pei-Jer Chen, Jung-Jung Mu, Wei-Kuang Chi, Tso-Liang Kao, Lih-Hwa Hwang, and Ding-Shinn Chen. "Assembly of Hepatitis Delta Virus-like Empty Particles in Yeast." Virology 236, no. 2 (September 1997): 374–81. http://dx.doi.org/10.1006/viro.1997.8743.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Li, T. C., Y. Yamakawa, K. Suzuki, M. Tatsumi, M. A. Razak, T. Uchida, N. Takeda, and T. Miyamura. "Expression and self-assembly of empty virus-like particles of hepatitis E virus." Journal of virology 71, no. 10 (1997): 7207–13. http://dx.doi.org/10.1128/jvi.71.10.7207-7213.1997.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Hainisch, Edmund K., Christoph Jindra, Reinhard Kirnbauer, and Sabine Brandt. "Papillomavirus-Like Particles in Equine Medicine." Viruses 15, no. 2 (January 25, 2023): 345. http://dx.doi.org/10.3390/v15020345.

Повний текст джерела
Анотація:
Papillomaviruses (PVs) are a family of small DNA tumor viruses that can induce benign lesions or cancer in vertebrates. The observation that animal PV capsid-proteins spontaneously self-assemble to empty, highly immunogenic virus-like particles (VLPs) has led to the establishment of vaccines that efficiently protect humans from specific PV infections and associated diseases. We provide an overview of PV-induced tumors in horses and other equids, discuss possible routes of PV transmission in equid species, and present recent developments aiming at introducing the PV VLP-based vaccine technology into equine medicine.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Huynh, Nhung T., Emma L. Hesketh, Pooja Saxena, Yulia Meshcheriakova, You-Chan Ku, Linh T. Hoang, John E. Johnson, Neil A. Ranson, George P. Lomonossoff, and Vijay S. Reddy. "Crystal Structure and Proteomics Analysis of Empty Virus-like Particles of Cowpea Mosaic Virus." Structure 24, no. 4 (April 2016): 567–75. http://dx.doi.org/10.1016/j.str.2016.02.011.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Richterová, Zuzana, David Liebl, Martin Horák, Zdena Palková, Jitka Štokrová, Pavel Hozák, Jan Korb, and Jitka Forstová. "Caveolae Are Involved in the Trafficking of Mouse Polyomavirus Virions and Artificial VP1 Pseudocapsids toward Cell Nuclei." Journal of Virology 75, no. 22 (November 15, 2001): 10880–91. http://dx.doi.org/10.1128/jvi.75.22.10880-10891.2001.

Повний текст джерела
Анотація:
ABSTRACT Electron and confocal microscopy were used to observe the entry and the movement of polyomavirus virions and artificial virus-like particles (VP1 pseudocapsids) in mouse fibroblasts and epithelial cells. No visible differences in adsorption and internalization of virions and VP1 pseudocapsids (“empty” or containing DNA) were observed. Viral particles entered cells internalized in smooth monopinocytic vesicles, often in the proximity of larger, caveola-like invaginations. Both “empty” vesicles derived from caveolae and vesicles containing viral particles were stained with the anti-caveolin-1 antibody, and the two types of vesicles often fused in the cytoplasm. Colocalization of VP1 with caveolin-1 was observed during viral particle movement from the plasma membrane throughout the cytoplasm to the perinuclear area. Empty vesicles and vesicles with viral particles moved predominantly along microfilaments. Particle movement was accompanied by transient disorganization of actin stress fibers. Microfilaments decorated by the VP1 immunofluorescent signal could be seen as concentric curves, apparently along membrane structures that probably represent endoplasmic reticulum. Colocalization of VP1 with tubulin was mostly observed in areas close to the cell nuclei and on mitotic tubulin structures. By 3 h postinfection, a strong signal of the VP1 (but no viral particles) had accumulated in the proximity of nuclei, around the outer nuclear membrane. However, the vast majority of VP1 pseudocapsids did not enter the nuclei.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Hord, M., W. Villalobos, A. V. Macaya-Lizano, and C. Rivera. "Chayote Mosaic, a New Disease in Sechium edule Caused by a Tymovirus." Plant Disease 81, no. 4 (April 1997): 374–78. http://dx.doi.org/10.1094/pdis.1997.81.4.374.

Повний текст джерела
Анотація:
A sap-transmissible virus was isolated from chayote (Sechium edule) in Costa Rica. Infected plants showed chlorotic spots and rings, and blotchy mosaics, which often coalesced to give a complete mosaic and leaf deformation. By electron microscopy, spherical virus-like particles of approximately 29 nm in diameter were visible, and cytological changes associated with the chloroplasts were observed. The virus particles sedimented in sucrose density gradients as two components, a top component of empty protein shells and a bottom component of electron-dense particles. Electrophoretic analysis showed a single-stranded RNA of approximately 5.7 kb and capsid protein (CP) subunits of ∼22 kDa. The virus was identified as a member of the tymovirus group on the basis of particle morphology, size, sedimentation in sucrose gradients, cytopathological effects, and capsid protein and genome properties, and it was tentatively named chayote mosaic virus (ChMV).
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Ammar, E. D., R. E. Gingery, and L. R. Nault. "Cytopathology and ultrastructure of mild and severe strains of maize chlorotic dwarf virus in maize and johnsongrass." Canadian Journal of Botany 71, no. 5 (May 1, 1993): 718–24. http://dx.doi.org/10.1139/b93-083.

Повний текст джерела
Анотація:
In maize leaves experimentally infected with various isolates or strains of maize chlorotic dwarf virus, including a newly characterized strain (M1), and in naturally infected johnsongrass, only two types of cytoplasmic inclusions were consistently observed: (i) quasi-spherical electron-dense granular inclusions, and (ii) curved or straight bundles of fibrous inclusions. Both types were detected by light and (or) electron microscopy in vascular parenchyma and phloem cells, and less frequently in bundle-sheath and adjacent mesophyll cells. The dense granular inclusions usually contained numerous isometric virus-like particles, some of which may have been released into the surrounding cytoplasm. However, a high proportion of these inclusions in cells infected with the mild type strain and a type-like isolate (M8) were either devoid of or contained very few viruslike particles. In maize leaves infected with the white stripe (WS) isolate, the chloroplasts were markedly deformed; in leaves of stunted plants doubly infected with M8 and the serologically distinct M1 strain, some phloem cells appeared degenerated. Electron microscopy of preparations of purified M1 stained with uranyl acetate revealed both stain-impenetrable full particles and stain-penetrable empty or partially empty particles. Both full and apparently empty particles were also found in cells of maize leaves infected with M1, whereas with other strains and isolates, mainly full particles were found both in situ and in vitro. Key words: maize chlorotic dwarf virus, cytopathology, ultrastructure, maize, johnsongrass.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Bardi, Giuseppe. "Nanometric Virus-Like Particles: Key Tools for Vaccine and Adjuvant Technology." Vaccines 8, no. 3 (July 31, 2020): 430. http://dx.doi.org/10.3390/vaccines8030430.

Повний текст джерела
Анотація:
The ideal vaccine should trigger a specific response against pathogens and induce the immune system memory to be prepared for eventual following infections. Although different approaches to develop new vaccines are currently taken, several of the features of natural pathogens that allow a tailored immune reaction are difficult to mimic. The viral capsids are the physical interface between a virus and the host defense machinery which recognizes specific patterns of the viral supramolecular complexes. Therefore, empty viral particles deprived of their genomes represent optimal targets to induce immune reactions with several advantages for vaccination and adjuvant realization.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Suárez, Cristina, María L. Salas, and Javier M. Rodríguez. "African Swine Fever Virus Polyprotein pp62 Is Essential for Viral Core Development." Journal of Virology 84, no. 1 (October 21, 2009): 176–87. http://dx.doi.org/10.1128/jvi.01858-09.

Повний текст джерела
Анотація:
ABSTRACT One of the most characteristic features of African swine fever virus gene expression is its use of two polyproteins, pp220 and pp62, to produce several structural proteins that account for approximately 32% of the total protein virion mass. Equimolecular amounts of these proteins are the major components of the core shell, a thick protein layer that lies beneath the inner envelope, surrounding the viral nucleoid. Polyprotein pp220, which is located immediately underneath the internal envelope, is essential for the encapsidation of the core of the viral particle. In its absence, the infection produces essentially coreless particles. In this study we analyzed, by means of an IPTG (isopropyl-β-d-thiogalactopyranoside)-inducible virus, the role of polyprotein pp62 in virus assembly. Polyprotein pp62 is indispensable for viral replication. The repression of polyprotein pp62 expression does not alter late gene expression or the proteolytic processing of the polyprotein pp220. However, it has a profound impact on the subcellular localization of polyprotein pp220. Electron microscopy studies revealed that polyprotein pp62 is necessary for the correct assembly and maturation of the core of the viral particle. Its repression leads to the appearance of a significant fraction of empty particles, to an increase in the number of immature-like particles, and to the accumulation of defective particles. Immunoelectron microscopy analysis showed a clear correlation between the amount of polyprotein pp62, the quantity of polyprotein pp220, and the state of development of the core, suggesting that the complete absence of polyprotein pp62 during morphogenesis would produce a homogenous population of empty particles.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Ren, Jingshan, Xiangxi Wang, Ling Zhu, Zhongyu Hu, Qiang Gao, Pan Yang, Xuemei Li, et al. "Structures of Coxsackievirus A16 Capsids with Native Antigenicity: Implications for Particle Expansion, Receptor Binding, and Immunogenicity." Journal of Virology 89, no. 20 (August 12, 2015): 10500–10511. http://dx.doi.org/10.1128/jvi.01102-15.

Повний текст джерела
Анотація:
ABSTRACTEnterovirus 71 (EV71) and coxsackievirus A16 (CVA16) are the primary causes of the epidemics of hand-foot-and-mouth disease (HFMD) that affect more than a million children in China each year and lead to hundreds of deaths. Although there has been progress with vaccines for EV71, the development of a CVA16 vaccine has proved more challenging, and the EV71 vaccine does not give useful cross-protection, despite the capsid proteins of the two viruses sharing about 80% sequence identity. The structural details of the expanded forms of the capsids, which possess nonnative antigenicity, are now well understood, but high resolution information for the native antigenic form of CVA16 has been missing. Here, we remedy this with high resolution X-ray structures of both mature and natural empty CVA16 particles and also of empty recombinant viruslike particles of CVA16 produced in insect cells, a potential vaccine antigen. All three structures are unexpanded native particles and antigenically identical. The recombinant particles have recruited a lipid moiety to stabilize the native antigenic state that is different from the one used in a natural virus infection. As expected, the mature CVA16 virus is similar to EV71; however, structural and immunogenic comparisons highlight differences that may have implications for vaccine production.IMPORTANCEHand-foot-and-mouth disease is a serious public health threat to children in Asian-Pacific countries, resulting in millions of cases. EV71 and CVA16 are the two dominant causative agents of the disease that, while usually mild, can cause severe neurological complications, leading to hundreds of deaths. EV71 vaccines do not provide protection against CVA16. A CVA16 vaccine or bivalent EV71/CVA16 vaccine is therefore urgently needed. We report atomic structures for the mature CVA16 virus, a natural empty particle, and a recombinant CVA16 virus-like particle that does not contain the viral genome. All three particles have similar structures and identical antigenicity. The recombinant particles, produced in insect cells (a system suitable for making vaccine antigen), are stabilized by recruiting from the insect cells a small molecule that is different from that used by the virus in a normal infection. We present structural and immunogenic comparisons with EV71 to facilitate structure-based drug design and vaccine development.
Стилі APA, Harvard, Vancouver, ISO та ін.

Дисертації з теми "Empty virus like particles"

1

Ross, James Finnian. "Reengineering bacterial toxins into virus-like particles." Thesis, University of Leeds, 2013. http://etheses.whiterose.ac.uk/6464/.

Повний текст джерела
Анотація:
The re-design and controlled self-assembly of natural systems into non-natural functional products is a quickly developing area of Synthetic Biology. Specifically, the manipulation of existing, and the introduction of new protein-protein interactions will allow great advances in bionanotechnology. In nature, protein-protein assemblies mediate many cellular processes and exhibit complex and efficient functions. It is thus rational to assume human-guided biomolecular assemblies could embody equally complex functionality designed to address current human needs. Here we present the design and preparation of a Virus-Like Particle (VLP) engineered from the cholera toxin B-subunit (CTB). This was achieved via the de novo design of a protein-protein interface between CTB subunits consisting of coiled-coil C-terminal extensions and modification to the CTB surface. A combination of computational methods was used to suggest mutations which should reduce the ΔΔG of interaction across the interface. CTB is a natural homopentamer with inbuilt cell targeting and endocytic triggering mechanism. Future applications for the VLP could include use as a drug delivery vehicle to transport protected therapeutic agents to targeted cell types. Through our investigations it became apparent that the CTB-VLP structures behaved in a similar manner to naturally occurring virus coat proteins, which suggests the successful biomimicry of these complex systems. This study provides a basis for the development of further VLPs from other homomultimeric proteins, especially further classes of homopentameric bacterial toxins.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Ruiss, Romana. "Induktion Epstein-Barr Virus-spezifischer Immunantworten durch Exosomen und Virus-like Particles." Diss., lmu, 2010. http://nbn-resolving.de/urn:nbn:de:bvb:19-119153.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Mažeikė, Eglė. "Generation of anticancer vaccine based on virus-like particles." Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2011. http://vddb.laba.lt/obj/LT-eLABa-0001:E.02~2011~D_20110621_164205-79199.

Повний текст джерела
Анотація:
In this dissertation the investigation of potential applications of hamster polyomavirus (HaPyV) major capsid protein VP1 based chimeric virus-like particles (VLPs) harboring CTL epitopes for anticancer vaccine development is presented. The objective of this study was to investigate the potential of recombinant HaPyV VP1 based VLPs for anticancer vaccine generation in model systems, including investigation of VP1 applicability for heterologous CTL epitopes insertions, VLPs assembly and ability to induce insert specific immune response in vivo. HaPyV VP1 VLPs carrying CLT epitopes derived from different proteins were generated, most suitable positions for insertion into VP1 protein were selected, the ways to improve assembly and yield of the chimeric VLPs were determined and new VLPs purification procedure was created allowing to purify VLPs cheaper, faster and more efficiently. HaPyV VP1 based VLPs ability to induce CTL immune response in vivo was evaluated for the first time. It was demonstrated that model chimeric VLPs were able to stimulate antigen specific CTL cells in vitro and in vivo, induced insert specific humoral and CTL immune response in vivo and protected mice from insert specific virus infection and antigen-specific tumor growth. Presented data confirmed that HaPyV protein VP1 is universal carrier for CTL epitopes, capable to tolerate insertions, to form VLPs and to induce effective, long lasting immune response against inserted antigens in vivo.
Disertacijoje yra aprašomas perspektyvų panaudoti žiurkėno poliomos viruso (HaPyV) pagrindinio struktūrinio baltymo VP1 formuojamas į virusus panašias daleles priešvėžinių vakcinų kūrimui tyrimas. Pagrindinis disertacijos darbo tikslas buvo modelinėse sistemose parodyti rekombinantinių HaPyV VP1 baltymų formuojamų į virusus panašių dalelių panaudojimo priešvėžinių vakcinų kūrimui galimybes, įvertinant svetimų CTL epitopų įterpimo į VP1 baltymą toleravimą, VPD formavimosi efektyvumą bei sukeltą įterptam antigenui specifinį imuninį atsaką. Disertacijoje atlikta tyrimo srities literatūros apžvalga, smulkiai aprašomi darbe naudoti metodai, atlikti eksperimentai, pateikiami bei analizuojami gauti rezultatai. Darbe pirmą kartą buvo nuodugniai ištirtos HaPyV viruso VP1 baltymo formuojamų VPD savybės, parodytas jų tinkamumas būti CTL epitopų nešikliais, ištirtos įterpimui palankiausios VP1 baltymo vietos, išbandyti nauji VPD gavimo ir gryninimo būdai, pagerinantys chimerinių VPD formavimąsi bei išeigas. Panaudojant modelines chimerines VPD in vivo buvo ištirtas chimerinių HaPyV VP1 pagrindu sukonstruotų VPD sukeliamas humoralinis ir ląstelinis imuninis atsakas. Gauti rezultatai parodė, kad HaPyV VP1 baltymas yra vienas iš nedaugelio virusų struktūrinių baltymų, kurie ne tik formuoja VPD, bet pasižymi ir universaliomis baltymo – nešiklio savybėmis, o in vivo sukelia efektyvų, ilgalaikį, įterptam epitopui specifinį imuninį atsaką.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Zhang, Naru, and 张娜茹. "Study on influenza virus-like particles and ssDNA aptamers." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/200167.

Повний текст джерела
Анотація:
Since there is an urgent need for development of vaccines and antiviral agents to combat influenza pandemics, this study aimed to develop influenza virus-like particles (VLPs) and aptamers targeting the virus particles as vaccine and antiviral agent candidates. Influenza VLPs containing three structural proteins of hemagglutinin (HA), neuraminidase (NA) and matrix 1 (M1) derived from influenza A/Hong Kong/01/2009 (H1N1) virus (HK/01) were constructed using a Bac-to-Bac baculovirus expression system. The expressed VLPs were purified by sucrose density gradient ultracentrifugation and characterized by Western blotting analysis and transmission electron microscopy. The immune responses and protective efficacy induced by VLPs were compared with those elicited by the clinically used Panenza vaccine in BALB/c mouse model. The results showed that two-dose vaccination with both VLP and the Panenza vaccine could confer complete protection. Single-dose vaccination with VLP could also provide 100% protection against lethal virus challenge, whereas single dose of an equal amount (based on HA content) of the Panenza vaccination just provided incomplete protection (67% survival rate) against the lethal virus challenge. Compared to the Panenza vaccination, the VLP vaccination could induce higher and broader antibody responses and higher viral specific T help (Th) cell and cytotoxic T lymphocyte (CTL) responses. Notably, a novel finding in this study is that the VLP vaccination could induce antibodies to inhibit virus release from infected MDCK cells, although the underlined mechanism needed to be further studied. These results indicated that influenza VLP might be a more effective and safe vaccine candidate which could be developed into an alternative vaccine for the control of epidemic and pandemic influenza in the future. To develop aptamers as antiviral agents against influenza, I sought to use influenza VLPs as target for ssDNA aptamer selection. After 11 rounds of selection using the systemic evolution of ligandsby exponential enrichment (SELEX),the recovered DNA molecules were PCR-amplified, gel purified and cloned into pCR-Blunt II TOPO vector for sequencing. The sequencing results showed that one aptamer Va-1 was markedly enriched, which was accounted for 59% (13/22) of the selected aptamers. Compared to the other non-enriched aptamers, the enriched aptamer Va-1 showed the highest binding affinity to the UV inactivated influenza HK/01 virus. It was also shown that the aptamer Va-1 specifically bound to the HK/01 stain while it could not bind other respiratory viruses even the PR8 strain within the H1N1 subtype. It was further demonstrated that the aptamer Va-1 could only bind to NA protein in a dose-dependent manner but not bind to HA and M1 proteins. Unfortunately, the selected aptamer did not show any antiviral effects. However, it may be potentially developed into a diagnostic and analytic agent because its binding activity was comparable with that of the commercial anti-NA antibody. In conclusion, the influenza VLPs may be a promising vaccine candidate for the control of influenza virus infection and the selected aptamer may be potentially developed into an alternative tool for influenza virus detection.
published_or_final_version
Microbiology
Doctoral
Doctor of Philosophy
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Hanslip, Simon John. "Production and assembly of human papillomavirus virus-like particles." Thesis, University of Cambridge, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.614258.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Överby, Anna K. "Uukuniemi virus-like particles : a model system for bunyaviral assembly /." Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-238-5/.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Venkatesh, Murthy Ambika Mosale. "Virus-like particles as a vaccine against porcine reproductive and respiratory syndrome virus." Thesis, Virginia Tech, 2013. http://hdl.handle.net/10919/50974.

Повний текст джерела
Анотація:
Porcine reproductive and respiratory syndrome (PRRS) is the most significant infectious disease currently affecting the swine industry worldwide. Several inactivated and modified live vaccines (MLV) have been developed to curb PRRSV infections. The unsatisfactory efficacy and safety of these vaccines, drives for the development of new generation PRRS universal vaccines. Virus like particles (VLPs) based vaccines are gaining increasing acceptance compared to subunit vaccines, as they present the antigens in more veritable conformation and are even readily recognized by the immune system. Hepatitis B virus (HBV) core antigen (HBcAg) is very well studied and has been successfully used as a carrier for more than 100 other viral sequences. In this study, hybrid HBcAg VLPs are generated by fusion of the conserved protective epitopes of PRRSV and expressed in E. coli. An optimized purification protocol that overcomes issues from ultracentrifugation is developed to obtain hybrid HBcAg VLP protein from the inclusion bodies. This hybrid HBcAg VLP protein self assembled to 23nm VLPs that were shown to block virus infection of susceptible cells when tested on MARC 145 cells. Therefore, the safety of non-infectious and non-replicable VLPs and production through low-cost E. coli fermentation may make this vaccine competitive against current vaccines on both efficacy and cost.
Master of Science
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Keller, Susanne Anita. "Cross-presentation of and cross-priming by virus-like particles /." [S.l.] : [s.n.], 2009. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=18320.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

González, Domínguez Irene. "Characterization and purification of HIV-1 based virus-like particles." Doctoral thesis, Universitat Autònoma de Barcelona, 2020. http://hdl.handle.net/10803/670546.

Повний текст джерела
Анотація:
Les virus-like particles (VLPs) de VIH han sorgit com una prometedora alternativa per al desenvolupament de nous candidats vacunals, però també per al disseny de teràpies avançades en el camp de la nanomedicina. En els últims anys, s’han desenvolupat diferents estratègies d’optimització per la producció de VLPs de VIH en cultius de cèl·lules animals. Malgrat aquests avanços, la manca d’informació sobre el procés de producció de les VLPs a nivell intracel·lular, la necessitat de mètodes analítics adients per la quantificació de les VLPs de VIH i la seua diferenciació d’altres estructures vesiculars, conegudes com extracellular vesicles (EVs), conjuntament amb la falta de mètodes de purificació, han limitat l’ús d’aquestes nanopartícules a la clínica. Per aquesta raó, la motivació d’aquesta tesis doctoral és aprofundir en els diferents paràmetres que participen en la generació de VLPs de VIH, així com el desenvolupament de nous mètodes d’anàlisi i purificació amb l’objectiu d’establir una plataforma de producció per la seua aplicació en l’àmbit de la biotecnologia.
Las virus-like particles (VLPs) derivadas del VIH han surgido como una potente alternativa para el desarrollo de nuevos candidatos vacunales, pero también para el diseño de terapias avanzadas en el campo de la nanomedicina. En los últimos años, se han optimizado diferentes estrategias para la producción de estas VLPs en cultivos de células animales. No obstante, el desconocimiento acerca de los diferentes pasos que acontecen a su producción a nivel intracelular, y que afectan al rendimiento de producción, la falta de métodos analíticos para su correcta caracterización y cuantificación, así como de su diferenciación de otras estructuras vesiculares, conocidas como extracelular vesicles (EVs), y la carencia de métodos de purificación adecuados, dificultan su aplicación en la clínica. Por todo ello, el objetivo de la presente tesis es investigar el proceso de producción de VLPs de VIH, así como desarrollar nuevos métodos analíticos y de purificación con el objetivo de establecer una plataforma de producción de estas nanopartículas para su uso en aplicaciones biotecnológicas.
HIV-1 virus-like particles (VLPs) have emerged as an interesting alternative for the development of novel vaccine candidates and delivery strategies of different cargos into different cells and tissues. Great efforts have been undertaken to optimize the generation of these nanoparticles in animal cell cultures. However, the limited understanding of its production at intracellular level, the need for analytical tools allowing its specific quantification over extracellular vesicles (EVs), and the few purification processes available hamper their clinical application. The aim of this thesis is to gain insight into the process parameters affecting HIV-1 Gag VLP production, and the development of analytical and purification methods to establish a complete platform for its clinical-grade production.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Roth, Jeanne-Francoise. "Regulation and assembly of the yeast Ty1 virus like particles." Thesis, University of Oxford, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.301254.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Книги з теми "Empty virus like particles"

1

Pumpens, Paul, and Peter Pushko. Virus-Like Particles: A Comprehensive Guide. Taylor & Francis Group, 2022.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Pumpens, Paul, and Peter Pushko. Virus-Like Particles: A Comprehensive Guide. Taylor & Francis Group, 2022.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Pumpens, Paul, and Peter Pushko. Virus-Like Particles: A Comprehensive Guide. Taylor & Francis Group, 2022.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Empty virus like particles"

1

Sainsbury, Frank, Pooja Saxena, Alaa A. A. Aljabali, Keith Saunders, David J. Evans, and George P. Lomonossoff. "Genetic Engineering and Characterization of Cowpea Mosaic Virus Empty Virus-Like Particles." In Methods in Molecular Biology, 139–53. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-751-8_11.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Mehlhorn, Heinz. "Virus like Particles." In Encyclopedia of Parasitology, 3019. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-43978-4_4387.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Mehlhorn, Heinz. "Virus-like Particles." In Encyclopedia of Parasitology, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27769-6_4387-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Pumpens, Paul, Peter Pushko, and Philippe Le Mercier. "Order Rowavirales." In Virus-Like Particles, 37–46. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/b22819-6.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Pumpens, Paul, Peter Pushko, and Philippe Le Mercier. "Order Cirlivirales." In Virus-Like Particles, 125–33. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/b22819-13.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Pumpens, Paul, Peter Pushko, and Philippe Le Mercier. "Order Piccovirales." In Virus-Like Particles, 109–24. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/b22819-12.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Pumpens, Paul, Peter Pushko, and Philippe Le Mercier. "Order Tymovirales." In Virus-Like Particles, 261–78. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/b22819-26.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Pumpens, Paul, Peter Pushko, and Philippe Le Mercier. "Order Bunyavirales." In Virus-Like Particles, 475–85. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/b22819-38.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Pumpens, Paul, Peter Pushko, and Philippe Le Mercier. "Prologue." In Virus-Like Particles, 1–9. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/b22819-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Pumpens, Paul, Peter Pushko, and Philippe Le Mercier. "Other Negative Single-Stranded RNA Viruses." In Virus-Like Particles, 505–9. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/b22819-40.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Empty virus like particles"

1

Dragnea, Bogdan. "Superfluorescent Virus-like Particles." In Novel Optical Materials and Applications. Washington, D.C.: OSA, 2021. http://dx.doi.org/10.1364/noma.2021.now1d.3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Liu, Qiang-Qiang, and Ming-Lian Wang. "The Current Status of Virus-like Particles." In 2015 International Conference on Medicine and Biopharmaceutical. WORLD SCIENTIFIC, 2016. http://dx.doi.org/10.1142/9789814719810_0036.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Fan, X. Z., L. Naves, N. P. Siwak, A. Brown, J. Culver, and R. Ghodssi. "VIRUS-LIKE-PARTICLES FOR NEXT GENERATION MICRO/NANO-BIOSENSORS." In 2014 Solid-State, Actuators, and Microsystems Workshop. San Diego: Transducer Research Foundation, 2014. http://dx.doi.org/10.31438/trf.hh2014.125.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Cheng, Xing-Jian, Yan-Ling Wu, Yoshimasa Tanaka, and Wen Zhang. "expression of norovirus virus-like particles in different systems." In 2014 International Conference on Computer Science and Electronic Technology. Paris, France: Atlantis Press, 2015. http://dx.doi.org/10.2991/iccset-14.2015.118.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Lin, Shih-Yeh, Cheng-Yu Chung, Yao-Chi Chung, Hsin-Yi Chiu, and Yu-Chen Hu. "Development of Enterovirus 71 Vaccine based on Virus-like Particles." In 14th Asia Pacific Confederation of Chemical Engineering Congress. Singapore: Research Publishing Services, 2012. http://dx.doi.org/10.3850/978-981-07-1445-1_411.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Feizpour, A., and B. M. Reinhard. "Approximating the Concentration of Lipids on the Surface of Virus-Like Particles through Plasmon Coupling." In CLEO: Applications and Technology. Washington, D.C.: OSA, 2014. http://dx.doi.org/10.1364/cleo_at.2014.am2p.3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Govind, Shubha. "Molecular analysis of immune-suppressive virus-like particles from cynipid waspLeptopilinaheterotoma,a generalist parasite ofDrosophila spp." In 2016 International Congress of Entomology. Entomological Society of America, 2016. http://dx.doi.org/10.1603/ice.2016.92691.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Lemke, Caitlin, Aliasger Salem, Arthur Krieg, and George Weiner. "Abstract 1417: Combination cancer immunotherapy using checkpoint blockade and intratumoral virus-like particles containing CpG ODN." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-1417.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Zhang, Z., M. Trippler, CI Real, M. Werner, T. Kemper, J. Treckmann, A. Paul, et al. "Hepatitis B virus particles activate toll-like receptor 2 signaling initial upon infection of primary human hepatocytes." In 35. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0038-1677305.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Rucker, Joseph, Riley Payne, Manu Mabila, Sonal Patel, Moniquetta Hall, Sharon Willis, and Benjamin J. Doranz. "Abstract 4635: Development of monoclonal antibodies against the GPCR CXCR4 and the ion channel Hv1 using virus-like particles." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4635.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Empty virus like particles"

1

Erdman, Matthew M., Brenda G. Crabtree, D. L. Hank Harris, and Kurt I. Kamrud. Immunization of Swine with Virus-like Replicon Particles: Proof of Concept. Ames (Iowa): Iowa State University, January 2007. http://dx.doi.org/10.31274/ans_air-180814-19.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Bacharach, Eran, W. Ian Lipkin, and Avigdor Eldar. Identification of the etiological agent of tilapia disease in the Lake of Galillee. United States Department of Agriculture, January 2013. http://dx.doi.org/10.32747/2013.7597932.bard.

Повний текст джерела
Анотація:
Background to the topic. Tilapines serve as the second most important group of farmed fish worldwide. Massive mortality of wild and cultured tilapia has been observed recently in Israel but the pathogen of this disease has not been identified. We proposed to identify the agent responsible for disease.  Major conclusions, solutions, achievements. We characterized the lesions in diseased fish and found that the brain was one of the affected organs. We found conditions to isolate from brains of diseased fish the etiological agent of the tilapia disease and to propagate it in cell culture. This led to the identification of the pathogen as a novel RNA virus, which we named Tilapia Lake Virus (TiLV). Electron microscopy of TiLV revealed virion-like particles and ether/chloroform-sensitivity assays demonstrated that TiLV is enveloped. Low passage TiLV, injected intra-peritoneally to tilapia, induced a disease with over 80% mortality. Cohabitation of healthy with diseased fish demonstrated that the disease is contagious, and that mortalities occur within few days. Fish surviving initial mortality were immune to further TiLV infections, suggesting the mounting of protective immune response. Screening cDNA libraries and high throughput sequencing determined the sequence of TiLV genome. This demonstrated that TiLV is indeed a novel virus and allowed the design of a PCRbased diagnostic test.  Implications, both scientific and agricultural. The characterization of a novel, emerging RNA virus that imposes major threat to the tilapia industry, enables the specific identification of the virus in tilapines. This allows prompt screening and surveillance of TiLV, epidemiological studies, and disease containment. This also potentially opens the way for the development of vaccines against TiLV.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Vakharia, Vikram, Shoshana Arad, Yonathan Zohar, Yacob Weinstein, Shamila Yusuff, and Arun Ammayappan. Development of Fish Edible Vaccines on the Yeast and Redmicroalgae Platforms. United States Department of Agriculture, February 2013. http://dx.doi.org/10.32747/2013.7699839.bard.

Повний текст джерела
Анотація:
Betanodaviruses are causative agents of viral nervous necrosis (VNN), a devastating disease of cultured marine fish worldwide. Betanodavirus (BTN) genome is composed of two single-stranded, positive-sense RNA molecules. The larger genomic segment, RNA1 (3.1 kb), encodes the RNA-dependent RNA polymerase, while the smaller genomic segment, RNA 2 (1.4kb), encodes the coat protein. This structural protein is the host-protective antigen of VNN which assembles to form virus-like particles (VLPs). BTNs are classified into four genotypes, designated red-spotted grouper nervous necrosis virus (RGNNV), barfin flounder nervous necrosis virus (BFNNV), tiger puffer nervous necrosis virus (TPNNV), and striped jack nervous necrosis virus (SJNNV), based on phylogenetic analysis of the coat protein sequences. RGNNV type is quite important as it has a broad host-range, infecting warm-water fish species. At present, there is no commercial vaccine available to prevent VNN in fish. The general goal of this research was to develop oral fish vaccines in yeast and red microalgae (Porphyridium sp.) against the RGNNV genotype. To achieve this, we planned to clone and sequence the coat protein gene of RGNNV, express the coat protein gene of RGNNV in yeast and red microalgae and evaluate the immune response in fish fed with recombinantVLPs antigens produced in yeast and algae. The collaboration between the Israeli group and the US group, having wide experience in red microalgae biochemistry, molecular genetics and large-scale cultivation, and the development of viral vaccines and eukaryotic protein expression systems, respectively, was synergistic to produce a vaccine for fish that would be cost-effective and efficacious against the betanodavirus infection.
Стилі APA, Harvard, Vancouver, ISO та ін.
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії